The US Food and Drug Administration (FDA) has accepted for priority review Regeneron and Sanofi’s supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a chronic, debilitating, and relapsing skin disease with underlying type-2 inflammation that typically occurs in an elderly population Priority review is granted to regulatory applications seeking approval for therapies that have the potential to provide significant improvement...